Auransa
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
550 Hamilton Ave Ste 230, Palo Alto, Cal...Phone Number
(650) 485-2908Website
www.auransa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Auransa
Auransa is a clinical stage, AI-native biopharma that utilizes a proprietary AI platform to analyze human disease data for the discovery of novel therapeutics aimed at improving cancer care. The company focuses on developing differentiated therapies through its innovative approach, which includes ongoing clinical trials for liver cancer and heart-safe chemotherapy. Auransa's target clients include patients with various diseases, particularly those responsive to their advanced therapies. With a strong foundation in genomics technology, Auransa is at the forefront of integrating data science into biological discovery.Explore more
Auransa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Auransa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Auransa has new funding data
Auransa, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Auransa
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Auransa had a recent Job posting/layoffs
Check if Auransa has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Auransa launches new products
Check out if Auransa is spiking on competitors!
Earning: See what the market has to say on Auransa recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Auransa
Compare insights from companies similar to Auransa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Auransa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Auransa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Auransa.
Auransa financials insights
Gather financial insights about Auransa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Debt
$377K
Auransa Tech Stack
A closer look at the technologies used by Auransa
Auransa News & Media
FDA Acceptance of Auransa's IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma
First compound to enter clinical trial stage from a pipeline of research programs based upon Auransa’s proprietary AI platform PALO ALTO, CA, UNITED STATES, November 3, 2022 /EINPresswire.com/ -- Auransa Inc., a clinical stage drug development company …Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases
PALO ALTO, Calif. and DURHAM, N.C., June 04, 2021 /PRNewswire/ -- Auransa, Inc., an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research...Auransa to Participate in BioCentury-BayHelix China Healthcare Summit 2019
PALO ALTO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need, today announced the company’s participation at the upcoming BioCentury-BayHelix China Healthcare Summit 2019. Pek Lum, Ph.D., Auransa’s chief executive officer, will deliver a corporate presentation and participate in a panel discussion at the conference, which is being held November 18-20 in SAuransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
Oral Presentation at the 13th Annual Conference of the International Liver Cancer Association Highlights Promising Antitumor Activity in Preclinical Cancer Model and HCC Cell Lines Oral Presentation at the 13th Annual Conference of the International Liver Cancer Association Highlights Promising Antitumor Activity in Preclinical Cancer Model and HCC Cell Lines
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Auransa
Sign Up For FreeTo access detailed company insights
Auransa is a clinical stage, AI-native biopharma that utilizes a proprietary AI platform to analyze human disease data for the discovery of novel therapeutics aimed at improving cancer care. The company focuses on developing differentiated therapies through its innovative approach, which includes ongoing clinical trials for liver cancer and heart-s... Read More
